Schistosoma japonicum is a parasitic trematode that causes schistosomiasis, a disease that affects millions of people worldwide, particularly in parts of Asia. Here are some critical points on the epidemiology of Schistosoma japonicum:
Geographic distribution: Schistosoma japonicum is primarily found in Asia, particularly in China, the Philippines, and Indonesia.
Modes of transmission: The parasite is transmitted to humans through contact with contaminated freshwater, which contains the intermediate host snail that harbors the parasite. Activities such as swimming, wading, and fishing in contaminated water sources can increase the risk of infection.
High-risk populations: Schistosoma japonicum tends to affect rural populations that rely on freshwater resources for their livelihoods. Farmers, fishermen, and others who work or live near freshwater sources are at high risk of infection.
Disease burden: Schistosoma japonicum is estimated to infect around 700,000 people in China alone and millions more globally. The disease can cause chronic illness, including liver and spleen damage, increasing susceptibility to other infections.
Control measures: Schistosoma japonicum include snail control, access to safe water and sanitation, mass drug administration, and health education. The WHO aims to eliminate schistosomiasis as a public health problem in several countries by 2025.
It has a complex life cycle involves different hosts, including freshwater snails and humans or other mammals.
Structure:
The adult form of Schistosoma japonicum is a flatworm about 1-2 cm long and 0.2-0.4 mm in width. The worm’s body is covered in a tough outer layer called the tegument, which protects it from the host’s immune system. It has a well-developed oral sucker and a ventral sucker, which help it to attach to the host’s blood vessels. It also has a digestive system, reproductive organs, and a nervous system.
Classification:
Schistosoma japonicum belongs to the phylum Platyhelminthes, class Trematoda, and order Strigeiformes. Within the genus Schistosoma, it is classified as a species of japonicum.
Kingdom: Animalia
Phylum: Platyhelminthes
Class: Trematoda
Order: Strigeiformes
Family: Schistosomatidae
Genus: Schistosoma
Species: Schistosoma japonicum
Several antigenic types of Schistosoma japonicum are defined based on the different surface antigens expressed by the parasite.
Some of the significant antigenic types of Schistosoma japonicum include:
Sj23: This is a surface antigen expressed by adult worms and has been shown to elicit a robust immune response in infected individuals.
Sj97: This is another surface antigen adult worms express as a potential vaccine candidate.
Sj62: This is a glycoprotein antigen expressed by the cercariae (the larval stage of the parasite) and has been shown to play a role in host-parasite interactions.
Sj31: This is a surface antigen expressed by the schistosomula (the early developmental stage of the parasite) and is involved in the invasion of host tissues.
These antigenic types of Schistosoma japonicum have been extensively studied in the context of vaccine development and immunodiagnosis of schistosomiasis.
The pathogenesis of Schistosoma japonicum infection is complex and involves multiple stages.
Penetration: The larvae of Schistosoma japonicum penetrate the skin of the host while the host is in contact with water that is infested with the parasite.
Migration: The larvae then migrate through the host’s skin, enter the bloodstream, and travel to the liver, where they mature into adult worms.
Adult worms: The adult worms of Schistosoma japonicum then mate and migrate to the mesenteric veins of the intestine, where they release eggs.
Eggs: Schistosoma japonicum can cause significant damage to the host tissues by inducing an inflammatory response, leading to granuloma formation and fibrosis. The eggs can also migrate to other organs, such as the liver, lungs, and brain, where they can cause similar damage.
Host response: The host response to Schistosoma japonicum infection is characterized by a Th2-type immune response, which involves the production of interleukin-4 (IL-4), interleukin-5 (IL-5), and interleukin-13 (IL-13). These cytokines activate eosinophils, macrophages, and T cells, which play a critical role in the clearance of the parasite.
Chronic phase: However, in the chronic phase of the infection, the host’s immune response becomes dysregulated, leading to tissue damage, fibrosis, and the development of chronic schistosomiasis.
The host defenses against Schistosoma japonicum include both innate and adaptive immune responses.
Innate immune response: It is the first defense against Schistosoma japonicum infection. It
includes the following mechanisms:
Physical barriers: The skin and mucous membranes of the host provide a physical barrier against the entry of Schistosoma japonicum larvae.
Complement system: A complement system is a group of proteins that can destroy invading microorganisms. The complement system can recognize and attack the Schistosoma japonicum larvae.
Natural killer cells can kill infected cells and prevent the spread of infection.
Macrophages: Macrophages are immune cells that can engulf and destroy Schistosoma japonicum larvae.
Adaptive immune response: these are more specific responses to Schistosoma japonicum infection. It includes the following mechanisms:
T cells: T cells are a type of immune cell that can recognize and attack Schistosoma japonicum larvae. T cells can also activate other immune cells, such as B cells.
B cells are immune cells that can produce antibodies against Schistosoma japonicum larvae. Antibodies can neutralize the Schistosoma japonicum larvae and prevent them from infecting other cells.
Cytokines are signaling molecules that activate and coordinate the immune response against Schistosoma japonicum infection.
The clinical manifestations of Schistosoma japonicum infection depend on the stage of the disease and the organ(s) affected.
Acute schistosomiasis (Katayama fever) occurs 4-8 weeks after the initial infection and is characterized by fever, malaise, headache, cough, abdominal pain, and diarrhea.
Chronic schistosomiasis can occur months or years after the initial infection and is characterized by various symptoms, depending on the organ(s) affected. The most common organs affected are the liver, spleen, and intestines.
Hepatosplenic schistosomiasis can cause hepatomegaly (enlarged liver), splenomegaly (enlarged spleen), abdominal pain, and portal hypertension.
Intestinal schistosomiasis can cause abdominal pain, diarrhea, and blood in the stool.
Schistosoma japonicum can also affect the lungs, causing pulmonary hypertension, cor pulmonale, and the central nervous system, causing seizures, paralysis, and other neurological symptoms.
The diagnosis of Schistosoma japonicum infection can be made using several methods, including:
Stool examination: The eggs of Schistosoma japonicum can be detected in stool samples using a microscope. However, it may take several weeks after infection for the eggs to appear, so that multiple stool samples may be needed for accurate diagnosis.
Serological tests: These tests detect antibodies produced by the body in response to the presence of the parasite. Enzyme-linked immunosorbent assay (ELISA) and indirect hemagglutination assay (IHA) are commonly used serological tests for Schistosoma japonicum infection.
Polymerase chain reaction (PCR): This test can detect the DNA of Schistosoma japonicum in blood, urine, or stool samples. PCR is highly sensitive and specific and can detect the parasite even at low levels.
Ultrasound: This imaging technique can be used to detect the presence of adult Schistosoma japonicum worms in the liver or other organs. Ultrasound is beneficial for detecting chronic infections and monitoring disease progression.
The control of Schistosoma japonicum can be achieved through a combination of different strategies, including:
Chemotherapy: The use of antiparasitic drugs such as praziquantel is the primary means of controlling schistosomiasis. Mass drug administration to entire communities at risk of infection is an effective strategy to reduce the prevalence and intensity of infection.
Vector control: Schistosoma japonicum requires a freshwater snail intermediate host to complete its life cycle. Snail control through molluscicides or biological agents can help reduce the transmission of the parasite.
Improved sanitation: Improved access to clean water and sanitation facilities can reduce the incidence of schistosomiasis by reducing exposure to contaminated water sources.
Health education: Educating communities about the transmission, prevention, and treatment of schistosomiasis can help to increase awareness and encourage behavior change, such as avoiding contact with contaminated water and seeking treatment when symptoms occur.
Environmental modification: Altering the environment to reduce exposure to contaminated water sources, such as building water treatment plants or constructing latrines, can also help control the disease’s spread.
Schistosoma japonicum is a parasitic trematode that causes schistosomiasis, a disease that affects millions of people worldwide, particularly in parts of Asia. Here are some critical points on the epidemiology of Schistosoma japonicum:
Geographic distribution: Schistosoma japonicum is primarily found in Asia, particularly in China, the Philippines, and Indonesia.
Modes of transmission: The parasite is transmitted to humans through contact with contaminated freshwater, which contains the intermediate host snail that harbors the parasite. Activities such as swimming, wading, and fishing in contaminated water sources can increase the risk of infection.
High-risk populations: Schistosoma japonicum tends to affect rural populations that rely on freshwater resources for their livelihoods. Farmers, fishermen, and others who work or live near freshwater sources are at high risk of infection.
Disease burden: Schistosoma japonicum is estimated to infect around 700,000 people in China alone and millions more globally. The disease can cause chronic illness, including liver and spleen damage, increasing susceptibility to other infections.
Control measures: Schistosoma japonicum include snail control, access to safe water and sanitation, mass drug administration, and health education. The WHO aims to eliminate schistosomiasis as a public health problem in several countries by 2025.
It has a complex life cycle involves different hosts, including freshwater snails and humans or other mammals.
Structure:
The adult form of Schistosoma japonicum is a flatworm about 1-2 cm long and 0.2-0.4 mm in width. The worm’s body is covered in a tough outer layer called the tegument, which protects it from the host’s immune system. It has a well-developed oral sucker and a ventral sucker, which help it to attach to the host’s blood vessels. It also has a digestive system, reproductive organs, and a nervous system.
Classification:
Schistosoma japonicum belongs to the phylum Platyhelminthes, class Trematoda, and order Strigeiformes. Within the genus Schistosoma, it is classified as a species of japonicum.
Kingdom: Animalia
Phylum: Platyhelminthes
Class: Trematoda
Order: Strigeiformes
Family: Schistosomatidae
Genus: Schistosoma
Species: Schistosoma japonicum
Several antigenic types of Schistosoma japonicum are defined based on the different surface antigens expressed by the parasite.
Some of the significant antigenic types of Schistosoma japonicum include:
Sj23: This is a surface antigen expressed by adult worms and has been shown to elicit a robust immune response in infected individuals.
Sj97: This is another surface antigen adult worms express as a potential vaccine candidate.
Sj62: This is a glycoprotein antigen expressed by the cercariae (the larval stage of the parasite) and has been shown to play a role in host-parasite interactions.
Sj31: This is a surface antigen expressed by the schistosomula (the early developmental stage of the parasite) and is involved in the invasion of host tissues.
These antigenic types of Schistosoma japonicum have been extensively studied in the context of vaccine development and immunodiagnosis of schistosomiasis.
The pathogenesis of Schistosoma japonicum infection is complex and involves multiple stages.
Penetration: The larvae of Schistosoma japonicum penetrate the skin of the host while the host is in contact with water that is infested with the parasite.
Migration: The larvae then migrate through the host’s skin, enter the bloodstream, and travel to the liver, where they mature into adult worms.
Adult worms: The adult worms of Schistosoma japonicum then mate and migrate to the mesenteric veins of the intestine, where they release eggs.
Eggs: Schistosoma japonicum can cause significant damage to the host tissues by inducing an inflammatory response, leading to granuloma formation and fibrosis. The eggs can also migrate to other organs, such as the liver, lungs, and brain, where they can cause similar damage.
Host response: The host response to Schistosoma japonicum infection is characterized by a Th2-type immune response, which involves the production of interleukin-4 (IL-4), interleukin-5 (IL-5), and interleukin-13 (IL-13). These cytokines activate eosinophils, macrophages, and T cells, which play a critical role in the clearance of the parasite.
Chronic phase: However, in the chronic phase of the infection, the host’s immune response becomes dysregulated, leading to tissue damage, fibrosis, and the development of chronic schistosomiasis.
The host defenses against Schistosoma japonicum include both innate and adaptive immune responses.
Innate immune response: It is the first defense against Schistosoma japonicum infection. It
includes the following mechanisms:
Physical barriers: The skin and mucous membranes of the host provide a physical barrier against the entry of Schistosoma japonicum larvae.
Complement system: A complement system is a group of proteins that can destroy invading microorganisms. The complement system can recognize and attack the Schistosoma japonicum larvae.
Natural killer cells can kill infected cells and prevent the spread of infection.
Macrophages: Macrophages are immune cells that can engulf and destroy Schistosoma japonicum larvae.
Adaptive immune response: these are more specific responses to Schistosoma japonicum infection. It includes the following mechanisms:
T cells: T cells are a type of immune cell that can recognize and attack Schistosoma japonicum larvae. T cells can also activate other immune cells, such as B cells.
B cells are immune cells that can produce antibodies against Schistosoma japonicum larvae. Antibodies can neutralize the Schistosoma japonicum larvae and prevent them from infecting other cells.
Cytokines are signaling molecules that activate and coordinate the immune response against Schistosoma japonicum infection.
The clinical manifestations of Schistosoma japonicum infection depend on the stage of the disease and the organ(s) affected.
Acute schistosomiasis (Katayama fever) occurs 4-8 weeks after the initial infection and is characterized by fever, malaise, headache, cough, abdominal pain, and diarrhea.
Chronic schistosomiasis can occur months or years after the initial infection and is characterized by various symptoms, depending on the organ(s) affected. The most common organs affected are the liver, spleen, and intestines.
Hepatosplenic schistosomiasis can cause hepatomegaly (enlarged liver), splenomegaly (enlarged spleen), abdominal pain, and portal hypertension.
Intestinal schistosomiasis can cause abdominal pain, diarrhea, and blood in the stool.
Schistosoma japonicum can also affect the lungs, causing pulmonary hypertension, cor pulmonale, and the central nervous system, causing seizures, paralysis, and other neurological symptoms.
The diagnosis of Schistosoma japonicum infection can be made using several methods, including:
Stool examination: The eggs of Schistosoma japonicum can be detected in stool samples using a microscope. However, it may take several weeks after infection for the eggs to appear, so that multiple stool samples may be needed for accurate diagnosis.
Serological tests: These tests detect antibodies produced by the body in response to the presence of the parasite. Enzyme-linked immunosorbent assay (ELISA) and indirect hemagglutination assay (IHA) are commonly used serological tests for Schistosoma japonicum infection.
Polymerase chain reaction (PCR): This test can detect the DNA of Schistosoma japonicum in blood, urine, or stool samples. PCR is highly sensitive and specific and can detect the parasite even at low levels.
Ultrasound: This imaging technique can be used to detect the presence of adult Schistosoma japonicum worms in the liver or other organs. Ultrasound is beneficial for detecting chronic infections and monitoring disease progression.
The control of Schistosoma japonicum can be achieved through a combination of different strategies, including:
Chemotherapy: The use of antiparasitic drugs such as praziquantel is the primary means of controlling schistosomiasis. Mass drug administration to entire communities at risk of infection is an effective strategy to reduce the prevalence and intensity of infection.
Vector control: Schistosoma japonicum requires a freshwater snail intermediate host to complete its life cycle. Snail control through molluscicides or biological agents can help reduce the transmission of the parasite.
Improved sanitation: Improved access to clean water and sanitation facilities can reduce the incidence of schistosomiasis by reducing exposure to contaminated water sources.
Health education: Educating communities about the transmission, prevention, and treatment of schistosomiasis can help to increase awareness and encourage behavior change, such as avoiding contact with contaminated water and seeking treatment when symptoms occur.
Environmental modification: Altering the environment to reduce exposure to contaminated water sources, such as building water treatment plants or constructing latrines, can also help control the disease’s spread.
Schistosoma japonicum is a parasitic trematode that causes schistosomiasis, a disease that affects millions of people worldwide, particularly in parts of Asia. Here are some critical points on the epidemiology of Schistosoma japonicum:
Geographic distribution: Schistosoma japonicum is primarily found in Asia, particularly in China, the Philippines, and Indonesia.
Modes of transmission: The parasite is transmitted to humans through contact with contaminated freshwater, which contains the intermediate host snail that harbors the parasite. Activities such as swimming, wading, and fishing in contaminated water sources can increase the risk of infection.
High-risk populations: Schistosoma japonicum tends to affect rural populations that rely on freshwater resources for their livelihoods. Farmers, fishermen, and others who work or live near freshwater sources are at high risk of infection.
Disease burden: Schistosoma japonicum is estimated to infect around 700,000 people in China alone and millions more globally. The disease can cause chronic illness, including liver and spleen damage, increasing susceptibility to other infections.
Control measures: Schistosoma japonicum include snail control, access to safe water and sanitation, mass drug administration, and health education. The WHO aims to eliminate schistosomiasis as a public health problem in several countries by 2025.
Structure and Classification
It has a complex life cycle involves different hosts, including freshwater snails and humans or other mammals.
Structure:
The adult form of Schistosoma japonicum is a flatworm about 1-2 cm long and 0.2-0.4 mm in width. The worm’s body is covered in a tough outer layer called the tegument, which protects it from the host’s immune system. It has a well-developed oral sucker and a ventral sucker, which help it to attach to the host’s blood vessels. It also has a digestive system, reproductive organs, and a nervous system.
Classification:
Schistosoma japonicum belongs to the phylum Platyhelminthes, class Trematoda, and order Strigeiformes. Within the genus Schistosoma, it is classified as a species of japonicum.
Kingdom: Animalia
Phylum: Platyhelminthes
Class: Trematoda
Order: Strigeiformes
Family: Schistosomatidae
Genus: Schistosoma
Species: Schistosoma japonicum
Antigenic Types
Several antigenic types of Schistosoma japonicum are defined based on the different surface antigens expressed by the parasite.
Some of the significant antigenic types of Schistosoma japonicum include:
Sj23: This is a surface antigen expressed by adult worms and has been shown to elicit a robust immune response in infected individuals.
Sj97: This is another surface antigen adult worms express as a potential vaccine candidate.
Sj62: This is a glycoprotein antigen expressed by the cercariae (the larval stage of the parasite) and has been shown to play a role in host-parasite interactions.
Sj31: This is a surface antigen expressed by the schistosomula (the early developmental stage of the parasite) and is involved in the invasion of host tissues.
These antigenic types of Schistosoma japonicum have been extensively studied in the context of vaccine development and immunodiagnosis of schistosomiasis.
Pathogenesis
The pathogenesis of Schistosoma japonicum infection is complex and involves multiple stages.
Penetration: The larvae of Schistosoma japonicum penetrate the skin of the host while the host is in contact with water that is infested with the parasite.
Migration: The larvae then migrate through the host’s skin, enter the bloodstream, and travel to the liver, where they mature into adult worms.
Adult worms: The adult worms of Schistosoma japonicum then mate and migrate to the mesenteric veins of the intestine, where they release eggs.
Eggs: Schistosoma japonicum can cause significant damage to the host tissues by inducing an inflammatory response, leading to granuloma formation and fibrosis. The eggs can also migrate to other organs, such as the liver, lungs, and brain, where they can cause similar damage.
Host response: The host response to Schistosoma japonicum infection is characterized by a Th2-type immune response, which involves the production of interleukin-4 (IL-4), interleukin-5 (IL-5), and interleukin-13 (IL-13). These cytokines activate eosinophils, macrophages, and T cells, which play a critical role in the clearance of the parasite.
Chronic phase: However, in the chronic phase of the infection, the host’s immune response becomes dysregulated, leading to tissue damage, fibrosis, and the development of chronic schistosomiasis.
Host Defences
The host defenses against Schistosoma japonicum include both innate and adaptive immune responses.
Innate immune response: It is the first defense against Schistosoma japonicum infection. It
includes the following mechanisms:
Physical barriers: The skin and mucous membranes of the host provide a physical barrier against the entry of Schistosoma japonicum larvae.
Complement system: A complement system is a group of proteins that can destroy invading microorganisms. The complement system can recognize and attack the Schistosoma japonicum larvae.
Natural killer cells can kill infected cells and prevent the spread of infection.
Macrophages: Macrophages are immune cells that can engulf and destroy Schistosoma japonicum larvae.
Adaptive immune response: these are more specific responses to Schistosoma japonicum infection. It includes the following mechanisms:
T cells: T cells are a type of immune cell that can recognize and attack Schistosoma japonicum larvae. T cells can also activate other immune cells, such as B cells.
B cells are immune cells that can produce antibodies against Schistosoma japonicum larvae. Antibodies can neutralize the Schistosoma japonicum larvae and prevent them from infecting other cells.
Cytokines are signaling molecules that activate and coordinate the immune response against Schistosoma japonicum infection.
Clinical Manifestations
The clinical manifestations of Schistosoma japonicum infection depend on the stage of the disease and the organ(s) affected.
Acute schistosomiasis (Katayama fever) occurs 4-8 weeks after the initial infection and is characterized by fever, malaise, headache, cough, abdominal pain, and diarrhea.
Chronic schistosomiasis can occur months or years after the initial infection and is characterized by various symptoms, depending on the organ(s) affected. The most common organs affected are the liver, spleen, and intestines.
Hepatosplenic schistosomiasis can cause hepatomegaly (enlarged liver), splenomegaly (enlarged spleen), abdominal pain, and portal hypertension.
Intestinal schistosomiasis can cause abdominal pain, diarrhea, and blood in the stool.
Schistosoma japonicum can also affect the lungs, causing pulmonary hypertension, cor pulmonale, and the central nervous system, causing seizures, paralysis, and other neurological symptoms.
Diagnosis
The diagnosis of Schistosoma japonicum infection can be made using several methods, including:
Stool examination: The eggs of Schistosoma japonicum can be detected in stool samples using a microscope. However, it may take several weeks after infection for the eggs to appear, so that multiple stool samples may be needed for accurate diagnosis.
Serological tests: These tests detect antibodies produced by the body in response to the presence of the parasite. Enzyme-linked immunosorbent assay (ELISA) and indirect hemagglutination assay (IHA) are commonly used serological tests for Schistosoma japonicum infection.
Polymerase chain reaction (PCR): This test can detect the DNA of Schistosoma japonicum in blood, urine, or stool samples. PCR is highly sensitive and specific and can detect the parasite even at low levels.
Ultrasound: This imaging technique can be used to detect the presence of adult Schistosoma japonicum worms in the liver or other organs. Ultrasound is beneficial for detecting chronic infections and monitoring disease progression.
Control
The control of Schistosoma japonicum can be achieved through a combination of different strategies, including:
Chemotherapy: The use of antiparasitic drugs such as praziquantel is the primary means of controlling schistosomiasis. Mass drug administration to entire communities at risk of infection is an effective strategy to reduce the prevalence and intensity of infection.
Vector control: Schistosoma japonicum requires a freshwater snail intermediate host to complete its life cycle. Snail control through molluscicides or biological agents can help reduce the transmission of the parasite.
Improved sanitation: Improved access to clean water and sanitation facilities can reduce the incidence of schistosomiasis by reducing exposure to contaminated water sources.
Health education: Educating communities about the transmission, prevention, and treatment of schistosomiasis can help to increase awareness and encourage behavior change, such as avoiding contact with contaminated water and seeking treatment when symptoms occur.
Environmental modification: Altering the environment to reduce exposure to contaminated water sources, such as building water treatment plants or constructing latrines, can also help control the disease’s spread.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
